8-K: Upstream Bio Reports Positive Phase 2 CRSwNP Results, Q3 2025 Financials

Upstream Bio announced positive top-line Phase 2 results for verekitug in CRSwNP, reported Q3 2025 financial results, and provided updates on its severe asthma and COPD trials.

Summary

• Positive top-line results from the VIBRANT Phase 2 trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) were reported in September 2025, showing statistically significant and clinically meaningful effects on primary and key secondary endpoints when administered once every 12 weeks.
• The VIBRANT study met its primary endpoint with a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001).
• Significant and clinically meaningful improvements were observed in key secondary endpoints, including a -0.8 (p=0.0003) reduction in nasal congestion score and a 76% (p=0.03) reduction in the need for surgery or systemic corticosteroids.
• Verekitug was generally well tolerated, demonstrating a favorable safety profile consistent with previous studies, with no serious adverse events (SAEs) observed.
• The company remains on track to report top-line results from the VALIANT Phase 2 trial in severe asthma in the first quarter of 2026.
• Enrollment is ongoing in the VENTURE Phase 2 trial in chronic obstructive pulmonary disease (COPD), with the first patient dosed in July 2025.
• As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $372.4 million, which is expected to fund planned operations through 2027.
• Research and development expenses increased to $33.0 million for the quarter ended September 30, 2025, compared to $15.4 million for the same period in 2024.
• General and administrative expenses increased to $5.5 million for the quarter ended September 30, 2025, compared to $4.1 million for the same period in 2024.
• Net loss for the quarter ended September 30, 2025, was $33.7 million, compared to a net loss of $16.0 million for the same period in 2024.

Sentiment

Score: 8

Explanation: The positive clinical trial results for verekitug in CRSwNP are a significant de-risking event, demonstrating strong efficacy and safety, positioning the drug favorably against existing biologics. The extended cash runway through 2027 provides financial stability for ongoing development. While operating expenses and net loss increased, this is expected for a clinical-stage biotech advancing multiple programs.

Positives

• Positive top-line results from the VIBRANT Phase 2 trial in CRSwNP demonstrated statistically significant and clinically meaningful effects on multiple endpoints.
• Verekitug met its primary endpoint in CRSwNP with a -1.8 reduction in placebo-adjusted endoscopic nasal polyp score (NPS) (p<0.0001).
• Significant improvements were observed in key secondary endpoints, including a -0.8 reduction in nasal congestion score (p=0.0003) and a 76% reduction in the need for surgery or systemic corticosteroids (p=0.03).
• Verekitug exhibited a favorable safety profile with no serious adverse events (SAEs) observed, consistent with previous studies.
• The observed clinical effect on endoscopic NPS suggests verekitug meets or exceeds that of other biologics in CRSwNP at 24 weeks, with an extended dosing interval of once every 12 weeks.
• On-track to report top-line results from the VALIANT Phase 2 trial in severe asthma in the first quarter of 2026.
• Cash, cash equivalents, and short-term investments of $372.4 million as of September 30, 2025, are expected to fund planned operations through 2027.
• New data identifying structural and mechanistic drivers of verekitug's potent disruption of TSLP signaling were presented at the European Respiratory Society Congress in September 2025, supporting its unique mechanism of action.

Negatives

• Net loss increased to $33.7 million for the quarter ended September 30, 2025, compared to $16.0 million for the same period in 2024.
• Research and development expenses significantly increased to $33.0 million for the quarter ended September 30, 2025, from $15.4 million in the prior year, primarily due to increased clinical and manufacturing expenses for verekitug programs.
• General and administrative expenses increased to $5.5 million for the quarter ended September 30, 2025, from $4.1 million in the prior year, driven by personnel-related expenses and professional service fees.

Risks

• Ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all.
• Risks and uncertainties related to the initiation, timing, progress, and results of clinical trials.
• Ability to fund development activities and achieve development goals.
• Dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved.
• Ability to attract, hire, and retain key personnel, and protect intellectual property.
• Financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved.
• Regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities.
• Risks related to competitors and the industry.

Future Outlook

Upstream Bio expects to report top-line results from the VALIANT Phase 2 trial in severe asthma in the first quarter of 2026. Following these data and discussions with regulators, the company will be well-positioned to advance Phase 3 development plans for verekitug in both CRSwNP and severe asthma. The company also plans to continue investments in CMC and drug delivery to further strengthen verekitug's clinical profile and utility for patients. Current cash, cash equivalents, and short-term investments are expected to fund planned operations through 2027.

Management Comments

• "During this quarter we reached an important milestone in verekitugs development and shared positive top-line results from VIBRANT, our Phase 2 trial in CRSwNP, which reinforced verekitugs differentiated clinical profile, including its potential for efficacy meeting or exceeding that of available biologics, with administration only four times per year."
• "We also continued to bolster our understanding of verekitug through translational research, including with the presentation of new data identifying structural and mechanistic drivers of verekitugs potent disruption of TSLP signaling by antagonism of the TSLP receptor at the European Respiratory Society Congress in September."
• "We remain on track to report top-line results from VALIANT, our Phase 2 trial in severe asthma in the first quarter of 2026. Guided by these data, and following discussion with regulators, we will be well-positioned to advance our Phase 3 development plans for verekitug in both CRSwNP and severe asthma."
• "In addition, we continue to make investments in CMC and drug delivery with the goal of further strengthening the clinical profile and utility of verekitug for patients."

Industry Context

Upstream Bio is developing verekitug, a TSLP receptor antagonist, which is currently the only known antagonist of its kind in clinical development. TSLP is a clinically validated driver of inflammatory responses, positioning verekitug upstream of multiple signaling cascades. This unique mechanism of action, coupled with the potential for differentiated efficacy and an extended dosing interval (once every 12 weeks), could provide a significant advantage in the competitive landscape of severe respiratory diseases such as CRSwNP, severe asthma, and COPD, addressing substantial unmet patient needs.

Comparison to Industry Standards

• Verekitug's observed clinical effect on endoscopic NPS in the VIBRANT Phase 2 trial suggests its efficacy "meets or exceeds that of other biologics in CRSwNP at 24 weeks."
• Verekitug's unique pharmacology may lead to differentiated efficacy and an extended dosing interval (once every 12 weeks) as compared to the current standard of care for inflammatory diseases.

Stakeholder Impact

• Shareholders: Positive clinical trial results and an extended cash runway are favorable, potentially increasing share value. Increased R&D expenses reflect necessary investment in the pipeline.
• Patients: Potential for a new, highly effective treatment with an extended dosing interval for severe respiratory diseases like CRSwNP, severe asthma, and COPD.
• Employees: Continued progress in clinical development and financial stability support ongoing operations and job security.
• Regulatory Authorities: Trial design using endpoints that could support product approval indicates alignment with regulatory expectations.

Next Steps

• Report top-line results from the VALIANT Phase 2 trial in severe asthma in the first quarter of 2026.
• Engage in discussions with regulatory authorities to advance Phase 3 development plans for verekitug in both CRSwNP and severe asthma.
• Continue enrollment in the VENTURE Phase 2 clinical trial in COPD.
• Continue making investments in CMC (Chemistry, Manufacturing, and Controls) and drug delivery to further strengthen verekitug's clinical profile and utility.
• Participate in upcoming investor conferences: 2025 Truist Securities Biopharma Symposium (November 6, 2025), Stifel 2025 Healthcare Conference (November 11, 2025), TD Cowen Immunology and Inflammation Summit (November 12, 2025), Piper Sandler 37th Annual Healthcare Conference (December 2, 2025), 8th Annual Evercore Healthcare Conference (December 4, 2025), and 44th Annual J.P. Morgan Healthcare Conference (January 12-15, 2026).

Key Dates

Recommendation

The positive Phase 2 results for verekitug in CRSwNP are a major de-risking event, demonstrating statistically significant and clinically meaningful efficacy, a favorable safety profile, and a potentially differentiated dosing schedule compared to existing biologics. This strengthens the commercial potential of verekitug and validates Upstream Bio's TSLP receptor antagonist approach. The company's strong cash position, funding operations through 2027, provides a solid financial foundation for advancing its pipeline, including upcoming severe asthma results. While increased R&D expenses contribute to a larger net loss, this is a necessary investment for a clinical-stage company with promising assets. The overall outlook is highly positive, suggesting significant upside potential.

Keywords

Upstream Bio, UPB, verekitug, CRSwNP, severe asthma, COPD, TSLP receptor antagonist, clinical trial, Phase 2, biotechnology, inflammatory diseases, respiratory disorders, nasal polyps, biologics, drug development, financial results